Skip to content
value.today

Seaport Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2024
Total raised
$226 M
1 round on record
Latest round
$226 M
Oct 2024
First round on record
Oct 2024
Today
Went public
See the company page

Seaport Therapeutics, Inc. is listed today as Seaport Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Seaport Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$226 MNo. 1$50 to $250 million

Seaport Therapeutics, Inc.: Raise no. 1, Oct 2024

Investors in this round

33 investors had bought by the notice of Oct 31, 2024: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Seaport Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$226 M of $226 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antony Loebel · Executive Officer
  • Daphne Zohar · Executive Officer, Director
  • Eric Green · Executive Officer
  • Lana Gladstein · Executive Officer
  • Michael Chen · Executive Officer
  • Bharatt I. Chowrira · Director
  • David I. Wheadon · Director
  • Denice I. Torres · Director
  • Eric Elenko · Director
  • James I. Healy · Director
  • Jason I. Pitts · Director
  • Robert I. Nelsen · Director
  • Steven Paul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lana Gladstein, General Counsel. Source: SEC Form D, newest notice filed Oct 31, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Seaport Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2024

That is all the official record says: Seaport Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Seaport Therapeutics, Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Seaport Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Antony LoebelPersonnot statednot statedHeld Series B preferred stock (Form 3, 2026)SEC Form 3
ARCH Venture Fund XII, L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
ARCH Venture Partners XII, LLCVenture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
ARCH Venture Partners XII, L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Lana GladsteinPersonnot statednot statedHeld Series B preferred stock (Form 3, 2026)SEC Form 3
Michael Cunyuan ChenPersonnot statednot statedHeld Series B preferred stock (Form 3, 2026)SEC Form 3
PureTech Health PLCCompanynot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
PureTech LYT, Inc.Companynot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Steven M. PaulPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.

Largest shareholders today

Institutions holding Seaport Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Seaport Therapeutics, Inc.
NameRoleNamed in
Antony LoebelExecutive officerOct 2024
Daphne ZoharExecutive officerOct 2024
Eric GreenExecutive officerOct 2024
Lana GladsteinExecutive officerOct 2024
Michael ChenExecutive officerOct 2024
Bharatt I. ChowriraDirectorOct 2024
Daphne ZoharDirectorOct 2024
David I. WheadonDirectorOct 2024
Denice I. TorresDirectorOct 2024
Eric ElenkoDirectorOct 2024
James I. HealyDirectorOct 2024
Jason I. PittsDirectorOct 2024
Robert I. NelsenDirectorOct 2024
Steven PaulDirectorOct 2024

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.